Nano-X Imaging (NNOX) GM discloses stock option and RSU holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Nano-X Imaging Ltd. executive Dara James, GM of the Source & Services Division, filed an initial ownership report showing equity-based compensation. James holds stock options over 100,000 ordinary shares at an exercise price of $49.68 expiring on January 18, 2031, plus options over 25,000 and 10,000 shares at $17.63 expiring in 2032, and 55,000 shares at $11.52 expiring in 2033. The filing also reports 39,474 ordinary shares consisting of restricted share units granted on February 5, 2026, with half vesting after 12 months and the rest after 24 months.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Dara James
Role
GM Source & Services Division
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy ordinary shares) — 100,000 shares (Direct);
Ordinary shares — 39,474 shares (Direct)
Footnotes (1)
- The ordinary shares reported in this row consist of shares underlying restricted share units that were granted to the Reporting Person on February 5, 2026, of which 50% will vest on the 12-month anniversary of the grant date and the remaining 50% will vest on the 24-month anniversary of the grant date. The options reported in this row were granted to the Reporting Person by the Issuer on January 18, 2021 and are fully vested and exercisable as of the date of this report. The options reported in this row were granted to the Reporting Person by the Issuer on March 28, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable on the four-year anniversary of the grant date (March 28, 2026). The options reported in this row were granted to the Reporting Person by the Issuer on August 11, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable on the four-year anniversary of the grant date (August 11, 2026). The options reported in this row were granted to the Reporting Person by the Issuer on May 23, 2023 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable on the four-year anniversary of the grant date (May 23, 2027).
FAQ
What does Nano-X Imaging (NNOX) Form 3 for Dara James report?
The Form 3 reports Dara James’ existing equity holdings in Nano-X Imaging, including stock options and restricted share units. It is an initial ownership statement, not a record of new share purchases or sales, and outlines exercise prices, expirations, and vesting schedules.
How many Nano-X Imaging stock options does Dara James hold on Form 3?
Dara James holds options over 100,000 ordinary shares at $49.68, 25,000 and 10,000 shares at $17.63, and 55,000 shares at $11.52. These options represent rights to buy Nano-X Imaging shares by specified expiration dates if exercised in the future.
What are the expiration dates of Dara James’ Nano-X Imaging options?
The options over 100,000 shares expire on January 18, 2031. Options over 25,000 and 10,000 shares expire in 2032, and options over 55,000 shares expire on May 23, 2033. Each grant maintains its own clearly defined expiration date.
Is Nano-X Imaging’s Form 3 for Dara James a buy or sell transaction?
The Form 3 is not a buy or sell report; it is an initial statement of beneficial ownership. It lists Dara James’ existing Nano-X Imaging options and restricted share units as of the reporting date, without indicating any new market transactions or exercises.